Core Outcome Research Measures in Anal Cancer (CORMAC)
General Information
There have been several trials and studies of interventions in patients with anal cancer, and these underpin current clinical practice. However, for each of these studies, several different endpoints have been reported. Lack of standardisation in reporting makes it very difficult to truly discuss likely outcomes of treatment with patients in the clinic i.e. informed consent.
The overall aim is to develop a core outcome set for the treatment of anal cancer which reflects the interests of patients, clinicians, commissioners, and trialists in order to facilitate decision-making by all stakeholders.
Link to protocol: http://bmjopen.bmj.com/content/7/11/e018726
Professor Andrew Renehan (supervisor and CI)
Professor Paula Williamson (supervisor)
Dr Caroline Sanders (supervisor)
Health Area
Target Population
Method(s)
Four work packages will be undertaken over 2 years:
• WP1: A systematic review of the literature on anal cancer treatments will be performed to identify a comprehensive list of clinical, patient-reported, healthcare 'process', resource, composite and surrogate outcomes reported in trials of the treatment of anal cancer.
• WP2: Semi-structured interviews with anal cancer survivors will be used to identify additional outcomes to supplement the long-list.
• WP3: Surveys of key stakeholders (patients, clinicians, commissioners) in three rounds of Delphi methodology will refine the outcome long-list into a core outcome set.
• WP4: Consensus meetings with key stakeholders will ratify the core outcome set.